Side-by-side · Research reference

SermorelinvsSurvodutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 3HUMAN-REVIEWED14/43 cited

BPhase 3HUMAN-REVIEWED25/54 cited

Sermorelin

GHRH 1-29 fragment · Short-acting

100–500 mcgPer doseMolteno 2013

Phase 3Evidence levelWalker 1994 Molteno 2013

~12 minHalf-lifeMolteno 2013

SQ · Pre-sleep · 1×/day

Survodutide

GLP-1/Glucagon Dual Agonist · Phase 3

Once weeklyFrequency

Phase 3Development stageRubino 2026

GLP-1/GCGRDual targetZimmermann 2026

SQ · Once Weekly

01Mechanism of Action

Parameter

Sermorelin

Survodutide

Primary target

Pituitary GHRH receptorWalker 1994

GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026 Zimmermann 2026

Pathway

GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisWalker 1994

Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026 Long 2026

Downstream effect

Pulsatile GH release; subsequent IGF-1 elevationMolteno 2013

Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026 Yathindra 2026

Feedback intact?

Yes — short pulse preserves feedback

—

Origin

Unmodified active 29-AA fragment of human GHRH (1-44)Walker 1994

—

Antibody development

—

02Dosage Protocols

Parameter

Sermorelin

Survodutide

Standard dose

100–500 mcg per injectionMolteno 2013

Not yet disclosed (Phase 3 ongoing)

SYNCHRONIZE Phase 3 program underway.Rubino 2026

Frequency

Once daily, pre-sleep

Once weekly

Lower / starter dose

100 mcg per dose

—

Evidence basis

Phase 3 (Geref pediatric); clinical practiceWalker 1994 Molteno 2013

Phase 2 RCT (obesity) · Phase 3 ongoing

Duration

8–12 weeks per cycle

—

Reconstitution

Bacteriostatic water

—

Timing

Pre-sleep, fasted preferred

—

Half-life

~12 min (plasma)Molteno 2013

Shorter than tesamorelin (~26 min) — simpler GHRH analogue.

—

Route

—

SubcutaneousYathindra 2026

Phase 2 findings

—

Significant weight loss and metabolic marker improvementYathindra 2026

MASH indication

—

Under investigation for MASH-cirrhosisPatil 2026 Andonie 2026

03Metabolic / Fat Loss Evidence

Parameter

Sermorelin

Survodutide

Primary fat target

—

Total body weight, visceral adipose tissue

Weight loss mechanism

—

Dual action: decreased energy intake + increased energy expenditureZimmermann 2026

Phase 2 efficacy

—

Significant weight loss demonstrated

Specific percentage not disclosed in abstracts.

Metabolic markers

—

Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026 Abulehia 2026 Andonie 2026

MRI-PDFF reduction

—

Hepatic fat reduction demonstrated in MASH trialsAndonie 2026

Network meta-analysis

—

Favorable efficacy profile vs other glucagon receptor agonists

Hepatic requirement

—

Hepatic GCGR required for maximal weight loss and metabolic effectsLong 2026

Energy expenditure

—

Increased energy expenditure contributes to weight lossZimmermann 2026

Comparative efficacy

—

Network meta-analysis shows competitive efficacy in GRA class

04Side Effects & Safety

Parameter

Sermorelin

Survodutide

Injection site reaction

Mild erythema, transient pain

—

Flushing / headache

Common transient effect

—

IGF-1 elevation

Modest at standard doses

—

Cancer risk

Contraindicated in active malignancy (GH/IGF-1 axis)

—

Pregnancy / OB

Avoid

—

Glucose handling

Generally neutral

—

GI symptoms

—

Diarrhea, nausea, fatigue — class effect of GLP-1 agonists

Safety profile

—

Network meta-analysis: comparable safety to other GRAs

Serious adverse events

—

Monitored in Phase 2/3; no unique safety signals reported

Detailed SAE data pending Phase 3 completion.

Injection site reactions

—

Expected with subcutaneous administration

Glucagon-related effects

—

Potential for tachycardia, increased blood pressure — theoretical glucagon effect

Absolute Contraindications

Sermorelin

·Active malignancy
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

Survodutide

·Personal or family history of medullary thyroid carcinoma (class effect)
·Multiple endocrine neoplasia syndrome type 2

Relative Contraindications

Sermorelin

·Untreated diabetes

Survodutide

·Severe GI disease (inflammatory bowel disease, gastroparesis)
·History of pancreatitis
·Cardiovascular disease (monitor closely for glucagon effects)

05Administration Protocol

Parameter

Sermorelin

Survodutide

1. Reconstitution

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.

Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.

2. Injection site

SQ — abdomen or thigh. Rotate sites.

Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.

3. Timing

Pre-sleep, fasted.

Once weekly, same day each week. Can be administered at any time of day, with or without meals.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.

5. Needle

29–31G, 4–8 mm insulin syringe.

Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.

06Stack Synergy

Sermorelin

+ Ipamorelin

Strong

View Ipamorelin →

Sermorelin (GHRH analogue) and ipamorelin (selective GHRP) form the prototypical GHRH+GHRP dual-axis stack at the lowest cost. Both peak within 30 min and produce a sharp physiological GH pulse without cortisol/prolactin elevation.

Sermorelin: 200–300 mcg SQ · pre-sleep
Ipamorelin: 200–300 mcg SQ · same injection
Primary benefit: Pulsatile GH stimulation, recovery, body composition

Raun 1998 Walker 1994

Survodutide

— no documented stacks